Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Petar Podlesniy is active.

Publication


Featured researches published by Petar Podlesniy.


Annals of Neurology | 2013

Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease

Petar Podlesniy; Joana Figueiro-Silva; Albert Lladó; Anna Antonell; Raquel Sánchez-Valle; Daniel Alcolea; Alberto Lleó; José Luis Molinuevo; Nuria Serra; Ramon Trullas

To identify a novel biochemical marker that precedes clinical symptoms in Alzheimer disease (AD).


Experimental Neurology | 2012

HIF-1α is neuroprotective during the early phases of mild hypoxia in rat cortical neurons

Beatriz López-Hernández; Inmaculada Posadas; Petar Podlesniy; Maria Alba Abad; Ramon Trullas; Valentín Ceña

Hypoxia-inducible factor 1α (HIF-1α) is a transcription factor that plays a key role in regulating the adaptive response to hypoxia. HIF-1α is stabilised during hypoxia and, after dimerisation with hypoxia-inducible factor 1β (HIF-1β), triggers the expression of various genes involved in cell cycle control and energy metabolism associated with cell survival. However, HIF-1α also regulates the expression of proapoptotic genes. The aim of this study was to ascertain the influence of HIF-1α on neurotoxicity evoked by hypoxia in rat cortical neurons. We found that mild hypoxia induces time-dependent neuronal death involving free radical production, mitochondrial depolarisation, cytochrome c release and caspase-3 activation. Lentivirus-mediated HIF-1α knockdown markedly strengthened all of these effects during the initial 24h of hypoxia, which suggests that HIF-1α plays a neuroprotective role in hypoxia-mediated neuronal death. After this initial period, the protective actions of HIF-1α disappeared over the course of the hypoxia-mediated HIF-1α stabilisation. Moreover, lentiviral-mediated overexpression of HIF-1α increased lactate dehydrogenase (LDH) A, one of the target genes for HIF-1α, but did not show protective actions on hypoxia-mediated neuronal death, indicating that the level of endogenous HIF-1α stabilisation achieved during hypoxia was already the maximum required for HIF-1α transcription activities. These results indicate that HIF-1α is neuroprotective in the early phases of hypoxia.


Alzheimers & Dementia | 2016

Mitochondrial DNA differentiates Alzheimer's disease from Creutzfeldt-Jakob disease

Petar Podlesniy; Franc Llorens; Ewa Golanska; Beata Sikorska; Pawel P. Liberski; Inga Zerr; Ramon Trullas

Low content of cell‐free mitochondrial DNA (mtDNA) in cerebrospinal fluid (CSF) is a biomarker of early stage Alzheimers disease (AD), but whether mtDNA is altered in a rapid neurodegenerative dementia such as Creutzfeldt‐Jakob disease is unknown.


The Journal of Neuroscience | 2012

NP1 Regulates Neuronal Activity-Dependent Accumulation of BAX in Mitochondria and Mitochondrial Dynamics

Kevin B. Clayton; Petar Podlesniy; Joana Figueiro-Silva; Guillermo López-Doménech; Lluis Benitez; Marta Enguita; Maria Alba Abad; Eduardo Soriano; Ramon Trullas

In cultured cerebellar granule neurons, low neuronal activity triggers the intrinsic program of apoptosis, which requires protein synthesis-dependent BAX translocation to mitochondria, a process that may underlie neuronal damage in neurodegeneration. However, the mechanisms that link neuronal activity with the induction of the mitochondrial program of apoptosis remain unclear. Neuronal pentraxin 1 (NP1) is a pro-apoptotic protein induced by low neuronal activity that is increased in damaged neurites in Alzheimers disease-affected brains. Here we report that NP1 facilitates the accumulation of BAX in mitochondria and regulates mitochondrial dynamics during apoptosis in rat and mouse cerebellar granule neurons in culture. Reduction of neuronal activity increases NP1 protein levels in mitochondria and contributes to mitochondrial fragmentation in a Bax-dependent manner. In addition, NP1 is involved in mitochondrial transport in healthy neurons. These results show that NP1 is targeted to mitochondria acting upstream of BAX and uncover a novel function for NP1 in the regulation of mitochondrial dynamics and trafficking during apoptotic neurodegeneration.


Neurobiology of Disease | 2016

Mitochondrial DNA in CSF distinguishes LRRK2 from idiopathic Parkinson's disease

Petar Podlesniy; Dolores Vilas; Peggy Taylor; Leslie M. Shaw; Eduardo Tolosa; Ramon Trullas

Mitochondrial DNA regulates mitochondrial function which is altered in both idiopathic and familial forms of Parkinsons disease. To investigate whether these two disease forms exhibit an altered regulation of mitochondrial DNA we measured cell free mitochondrial DNA content in cerebrospinal fluid (CSF) from idiopathic and LRRK2-related Parkinsons disease patients. The concentration of mitochondrial DNA was measured using a digital droplet polymerase chain reaction technique in a total of 98 CSF samples from a cohort of subjects including: 20 LRRK2(G2019S) mutation carriers with Parkinsons disease, 26 asymptomatic LRRK2(G2019S) mutation carriers, 31 patients with idiopathic Parkinsons disease and 21 first-degree relatives of LRRK2 Parkinsons disease patients without the mutation. Here we report that LRRK2(G2019S) mutation carriers with Parkinsons disease exhibit a high concentration of mitochondrial DNA in CSF compared with asymptomatic LRRK2(G2019S) mutation carriers and with idiopathic Parkinsons disease patients. In addition, idiopathic, but not LRRK2 Parkinsons disease is associated with low CSF concentration of α-synuclein. These results show that high mitochondrial DNA content in CSF distinguishes idiopathic from LRRK2-related Parkinsons disease suggesting that different biochemical pathways underlie neurodegeneration in these two disorders.


Scientific Reports | 2016

Distinct X-chromosome SNVs from some sporadic AD samples.

Alberto Gómez-Ramos; Petar Podlesniy; Eduardo Soriano; Jesús Ávila

Sporadic Alzheimer disease (SAD) is the most prevalent neurodegenerative disorder. With the development of new generation DNA sequencing technologies, additional genetic risk factors have been described. Here we used various methods to process DNA sequencing data in order to gain further insight into this important disease. We have sequenced the exomes of brain samples from SAD patients and non-demented controls. Using either method, we found a higher number of single nucleotide variants (SNVs), from SAD patients, in genes present at the X chromosome. Using the most stringent method, we validated these variants by Sanger sequencing. Two of these gene variants, were found in loci related to the ubiquitin pathway (UBE2NL and ATXN3L), previously do not described as genetic risk factors for SAD.


The Journal of Neuroscience | 2015

Neuronal Pentraxin 1 Negatively Regulates Excitatory Synapse Density and Synaptic Plasticity

Joana Figueiro-Silva; Agnès Gruart; Kevin B. Clayton; Petar Podlesniy; Maria Alba Abad; Xavier Gasull; José M. Delgado-García; Ramon Trullas

In mature neurons, the number of synapses is determined by a neuronal activity-dependent dynamic equilibrium between positive and negative regulatory factors. We hypothesized that neuronal pentraxin (NP1), a proapoptotic protein induced by low neuronal activity, could be a negative regulator of synapse density because it is found in dystrophic neurites in Alzheimers disease-affected brains. Here, we report that knockdown of NP1 increases the number of excitatory synapses and neuronal excitability in cultured rat cortical neurons and enhances excitatory drive and long-term potentiation in the hippocampus of behaving mice. Moreover, we found that NP1 regulates the surface expression of the Kv7.2 subunit of the Kv7 family of potassium channels that control neuronal excitability. Furthermore, pharmacological activation of Kv7 channels prevents, whereas inhibition mimics, the increase in synaptic proteins evoked by the knockdown of NP1. These results indicate that NP1 negatively regulates excitatory synapse number by modulating neuronal excitability and show that NP1 restricts excitatory synaptic plasticity.


Multiple Sclerosis Journal | 2018

Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment

Cyra E Leurs; Petar Podlesniy; Ramon Trullas; Lisanne J. Balk; Martijn D. Steenwijk; Arjan Malekzadeh; Fredrik Piehl; Bernard M. J. Uitdehaag; Joep Killestein; Jack van Horssen; Charlotte E. Teunissen

Background: Mitochondrial dysfunction is increasingly recognized as an important feature of multiple sclerosis (MS) pathology and may be relevant for clinical disease progression. However, it is unknown whether mitochondrial DNA (mtDNA) levels in the cerebrospinal fluid (CSF) associate with disease progression and therapeutic response. Objectives: To evaluate whether CSF concentrations of mtDNA in MS patients can serve as a marker of ongoing neuropathology and may be helpful to differentiate between MS disease subtypes. To explore the effect of disease-modifying therapies on mtDNA levels in the CSF. Methods: CSF mtDNA was measured using a digital polymerase chain reaction (PCR) CSF mtDNA in two independent MS cohorts. The cohorts included 92 relapsing-remitting multiple sclerosis (RRMS) patients, 40 progressive multiple sclerosis (PMS) patients (27 secondary progressive and 13 primary progressive), 50 various neurologic disease controls, and 5 healthy controls. Results: Patients with PMS showed a significant increase in CSF mtDNA compared to non-inflammatory neurologic disease controls. Patients with higher T2 lesion volumes and lower normalized brain volumes showed increased concentration of mtDNA. Patients treated with fingolimod had significantly lower mtDNA copy levels at follow-up compared to baseline. Conclusion: Our results showed a non-specific elevation of concentration of mtDNA in PMS patients. mtDNA concentrations respond to fingolimod and may be used to monitor biological effect of this treatment.


Archive | 2018

Biomarkers in Cerebrospinal Fluid: Analysis of Cell-Free Circulating Mitochondrial DNA by Digital PCR

Petar Podlesniy; Ramon Trullas

Cerebrospinal fluid (CSF) contains molecules directly linked with brain function because it permeates brain tissue. The analysis of protein biomarkers in CSF is currently recommended for the diagnosis of neurodegenerative disorders, but the clinical sensitivity and specificity are still being investigated. A major drawback is that most of the currently used biomarkers of neurodegenerative diseases are proteins that are found at very low concentrations in CSF and need to be measured by immunoassays that provide relative values, which sometimes are difficult to reproduce between laboratories. In contrast, the recent availability of digital PCR platforms allows the absolute quantification of nucleic acids at single-molecule resolution, but their presence in CSF has not been characterized. CSF contains cell-free mitochondrial DNA (mtDNA) and changes in the concentration of this nucleic acid are linked to neurodegeneration. Here we describe a method to measure the concentration of cell-free circulating mtDNA directly in unpurified CSF using droplet digital PCR with either hydrolysis probes or fluorescent DNA-binding dye methods. This protocol allows the detection and absolute quantification of mtDNA content in the CSF with high analytical sensitivity, specificity, and accuracy.


Scientific Reports | 2017

Absolute measurement of gene transcripts with Selfie-digital PCR

Petar Podlesniy; Ramon Trullas

Absolute measurement of the number of RNA transcripts per gene is necessary to compare gene transcription among different tissues or experimental conditions and to assess transcription of genes that have a variable copy number per cell such as mitochondrial DNA. Here, we present a method called Selfie-digital PCR that measures the absolute amount of an RNA transcript produced by its own coding DNA at a particular moment. Overcoming the limitations of previous approaches, Selfie-digital PCR allows for the quantification of nuclear and mitochondrial gene transcription in a strand-specific manner that is comparable among tissues and cell types that differ in gene copy number or metabolic state. Using Selfie-digital PCR, we found that, with the exception of the liver, different organs exhibit marked variations in mitochondrial DNA copy number but similar transcription of mitochondrial DNA heavy and light chains, thus suggesting a preferential role of mitochondrial DNA abundance over its transcription in organ function. Moreover, the strand-specific analysis of mitochondrial transcription afforded by Selfie-digital PCR showed that transcription of the heavy strand was significantly higher than that of the light strand in all the tissues studied.

Collaboration


Dive into the Petar Podlesniy's collaboration.

Top Co-Authors

Avatar

Ramon Trullas

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joana Figueiro-Silva

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar

Ramon Trullas

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Agnès Gruart

Pablo de Olavide University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Alberto Lleó

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Daniel Alcolea

Autonomous University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge